



#19

RECEIVED

APR 24 2003

TECH CENTER 1600/2900

RECEIVED

APR 23 2003

GROUP 1700




Figure 1A




Figure 1B





Figure 1C



IgG fractions

50 mg and 10 mg groups dosed 1qwk;

placebos dosed 1, 2 or 4 per month

visit 2 = pre-drug baseline


visit 11 = pre-dose sample

★ p < 0.05

★★ p < 0.01

Figure 3A

Figure 3B



(mean ± SEM)

★ p-value < 0.05

★★ p-value < 0.01




Figure 4A




Figure 4B




Figure 4C









Figure 4D








High Affinity




Low Affinity





■ Baseline
 ▨ 4 months


Figure 8



- * analysis includes 69 of 114 patients treated with LPJ 394
- * analysis includes 14 of 19 lupus flares from drug treated group


Figure 11A





* data represents 15 of 19 LJP flares and 14 of 23 placebo flares

Figure 12




* analysis includes 36 of 115 patients treated with placebo graph identifies 14 of 23 lupus flares from placebo treated group

Figure 13



Figure 16

Placebo n = 95
Active n = 91




¹ HDCC = First incidence of high dose corticosteroids +/- cyclophosphamide

² Major lupus flare: hospitalization (due to SLE), first occurrence of high dose prednisone, any cyclophosphamide, death due to SLE



Placebo n = 106
LJP 394 n = 105

Figure 17



1 HDCC = First incidence of high dose corticosteroids +/- cyclophosphamide
2 Major lupus flare: hospitalization (due to SLE), first occurrence of high dose prednisone, any cyclophosphamide, death due to SLE